Premedication to Reduce Amivantamab Associated Infusion Related Reactions
| 대상 질환 | Carcinoma, Non-Small-Cell Lung |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Janssen Research & Development, LLC |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 68 명 |
| 중재(약물) | Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib |
| 시작일 | 2023년 5월 18일 |
| 완료일 | 2024년 3월 29일 |
| 결과 공개일 | 2025년 10월 20일 |
요약
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.
Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1
| Cohort A: Dexamethasone 4 Milligrams (mg) | 83.3 Percentage of participants |
|---|---|
| Cohort A2: Dexamethasone 8 mg | 22.5 Percentage of participants |
| Cohort B: Montelukast 10 mg | 66.7 Percentage of participants |
| Cohort C: Methotrexate 25 mg | 83.3 Percentage of participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — M.D. Anderson Cancer Center
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)